Free Trial Information
BioCentury | Apr 30, 2012
Finance

Analyst tracks

...and biotechnology research analyst. Banker tracks Michael Manocchio was promoted to VP from associate at Morgan Joseph TriArtisan...
Read More
BioCentury | Mar 12, 2012
Financial News

Lpath completes private placement of units

...$9.3 million Units: 12.4 million Price: $0.75 (unit) Shares after offering: 73.7 million Placement agents: Morgan Joseph TriArtisan...
Read More
BioCentury | Jan 30, 2012
Financial News

Tvax Biomedical amends IPO

...shares at $9-$11 per share. The company also added Aegis as an underwriter and dropped Morgan Joseph TriArtisan...
Read More
BioCentury | Jan 2, 2012
Financial News

Lpath amends follow-on

...million Price prior: $1.15 Underwriters: Morgan Joseph TriArtisan; Summer Street Note: Lpath amended its offering to add Morgan Joseph TriArtisan...
Read More
BioCentury | Nov 14, 2011
Finance

Heartland IPOs

...$4.6 million in cash at June 30. Underwriters are Roth Capital Partners; Cantor Fitzgerald; and Morgan Joseph TriArtisan. ...
Read More
BioCentury | Nov 14, 2011
Financial News

Tvax Biomedical proposes IPO

...raised: Up to $40 million Shares: TBD Price: TBD Underwriters: Roth Capital Partners; Cantor Fitzgerald; Morgan Joseph TriArtisan WIR...
Read More
BioCentury | Nov 8, 2011
Financial News

Tvax Biomedical files for IPO

...up to $40 million in an IPO underwritten by Roth Capital Partners; Cantor Fitzgerald; and Morgan Joseph TriArtisan...
Read More
BioCentury | Jul 25, 2011
Financial News

NeoStem completes follow-on

...Units: 13.8 million Price: $1.20 (unit) Shares after offering: 96.6 million Underwriters: Lazard; JMP Securities; Morgan Joseph TriArtisan...
Read More
BioCentury | Jul 20, 2011
Financial News

NeoStem raises $16.5M

Cell therapy company NeoStem Inc. (NYSE-A:NBS) raised $16.5 million through the sale of 13.8 million units at $1.20 in a follow-on underwritten by Lazard; JMP; Morgan Joseph; TriArtisan; Maxim Group; and National Securities. Each unit...
Read More
BioCentury | Jun 13, 2011
Finance

Banker, Analyst, Venture Tracks

...for Europe. He was the head of pharmaceutical research at Morgan Stanley. Raghuram Selvaraju joined Morgan Joseph TriArtisan...
Read More
Items per page:
1 - 10 of 13
BioCentury | Apr 30, 2012
Finance

Analyst tracks

...and biotechnology research analyst. Banker tracks Michael Manocchio was promoted to VP from associate at Morgan Joseph TriArtisan...
Read More
BioCentury | Mar 12, 2012
Financial News

Lpath completes private placement of units

...$9.3 million Units: 12.4 million Price: $0.75 (unit) Shares after offering: 73.7 million Placement agents: Morgan Joseph TriArtisan...
Read More
BioCentury | Jan 30, 2012
Financial News

Tvax Biomedical amends IPO

...shares at $9-$11 per share. The company also added Aegis as an underwriter and dropped Morgan Joseph TriArtisan...
Read More
BioCentury | Jan 2, 2012
Financial News

Lpath amends follow-on

...million Price prior: $1.15 Underwriters: Morgan Joseph TriArtisan; Summer Street Note: Lpath amended its offering to add Morgan Joseph TriArtisan...
Read More
BioCentury | Nov 14, 2011
Finance

Heartland IPOs

...$4.6 million in cash at June 30. Underwriters are Roth Capital Partners; Cantor Fitzgerald; and Morgan Joseph TriArtisan. ...
Read More
BioCentury | Nov 14, 2011
Financial News

Tvax Biomedical proposes IPO

...raised: Up to $40 million Shares: TBD Price: TBD Underwriters: Roth Capital Partners; Cantor Fitzgerald; Morgan Joseph TriArtisan WIR...
Read More
BioCentury | Nov 8, 2011
Financial News

Tvax Biomedical files for IPO

...up to $40 million in an IPO underwritten by Roth Capital Partners; Cantor Fitzgerald; and Morgan Joseph TriArtisan...
Read More
BioCentury | Jul 25, 2011
Financial News

NeoStem completes follow-on

...Units: 13.8 million Price: $1.20 (unit) Shares after offering: 96.6 million Underwriters: Lazard; JMP Securities; Morgan Joseph TriArtisan...
Read More
BioCentury | Jul 20, 2011
Financial News

NeoStem raises $16.5M

Cell therapy company NeoStem Inc. (NYSE-A:NBS) raised $16.5 million through the sale of 13.8 million units at $1.20 in a follow-on underwritten by Lazard; JMP; Morgan Joseph; TriArtisan; Maxim Group; and National Securities. Each unit...
Read More
BioCentury | Jun 13, 2011
Finance

Banker, Analyst, Venture Tracks

...for Europe. He was the head of pharmaceutical research at Morgan Stanley. Raghuram Selvaraju joined Morgan Joseph TriArtisan...
Read More
Items per page:
1 - 10 of 13